SCHEMBL302211

SCHEMBL302211

CCCCCC(O)(CCCCC)C(O)CO

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FDPS P14324 9/20 0.39
GGPS1 O95749 6/20 0.39
LMNA P02545 2/20 0.38
CYP2D6 P10635 2/20 0.36
SPHK1 Q9NYA1 1/20 0.36
GMNN O75496 1/20 0.36
POLB P06746 1/20 0.36
THPO P40225 1/20 0.36
MTOR P42345 1/20 0.36
BLM P54132 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
CETP P11597 1/20 0.36
HTT P42858 1/20 0.36
UBE2N P61088 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2039696 1.00 FDPS (0.39) FDPSGGPS1LMNACYP2D6SPHK1
SCHEMBL139952 0.98 LMNA (0.41) FDPSGGPS1LMNACYP2D6SPHK1
SCHEMBL136611 0.98 LMNA (0.41) FDPSGGPS1LMNACYP2D6SPHK1
SCHEMBL5820256 0.98 LMNA (0.41) FDPSGGPS1LMNACYP2D6SPHK1
SCHEMBL5963212 0.98 LMNA (0.41) FDPSGGPS1LMNACYP2D6SPHK1
SCHEMBL25815 0.98 LMNA (0.41) FDPSGGPS1LMNACYP2D6SPHK1
SCHEMBL2226505 0.98 LMNA (0.41) FDPSGGPS1LMNACYP2D6SPHK1
SCHEMBL18863212 0.98 LMNA (0.41) FDPSGGPS1LMNACYP2D6SPHK1
SCHEMBL142854 0.98 LMNA (0.41) FDPSGGPS1LMNACYP2D6SPHK1
SCHEMBL1890334 0.98 LMNA (0.41) FDPSGGPS1LMNACYP2D6SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 718 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3576847-B1 SUNSCREEN COMPOSITIONS WITH NATURAL WAXES FOR IMPROVED WATER RESISTANCE EDGEWELL PERSONAL CARE BRANDS LLC (US) 2024-07-03 EP claimed
EP-2714004-B1 CONTROLLED RELEASE PEPTIDE FORMULATIONS CAMURUS AB (SE) 2024-05-15 EP claimed
EP-3917503-B1 METHODS OF PREPARING LIPID NANOPARTICLES MODERNATX INC (US) 2024-05-08 EP claimed
EP-3258789-B1 OIL BLENDS AND THEIR USE IN COMPOSITIONS FRUTAROM LTD (IL) 2024-05-01 EP claimed
EP-4082530-B1 PROTEASE INHIBITOR-CONTAINING COMPOSITIONS, COMPOSITIONS COMPRISING SAME, AND METHODS FOR PRODUCING AND USING SAME ORAMED LTD (IL) 2024-04-10 EP claimed
EP-3884783-B1 OIL AND FAT COMPOSITION KAO CORP (JP) 2024-04-03 EP claimed
EP-3879992-B1 LIQUID CREAMER AND METHOD FOR ITS PRODUCTION NESTLE SA (CH) 2024-02-28 EP claimed
EP-3879990-B1 LIQUID CREAMER NESTLE SA (CH) 2024-02-28 EP claimed
US-20240002430-A1 METHOD FOR PRODUCING PROTEIN COMPOSITIONS HOFFMAN-LA ROCHE INC. (US) 2024-01-04 US claimed
EP-3802762-B1 PROCESS FOR THE PRODUCTION OF DIGLYCERIDES DSM IP ASSETS BV (NL) 2023-12-13 EP claimed
EP-0287652-B1 SERUM-FREE MEDIUM FOR THE PROLIFERATION OF LYMPHOKINE-ACTIVATED KILLER CELLS LIFE TECHNOLOGIES INC (US) 1994-01-12 EP claimed
WO-1993011257-A2 PROCESS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING A RECEPTOR-DEPENDENT CELLULAR SIGNAL TRANSMISSION PATH BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 1993-06-10 WO claimed
EP-0532915-A2 Phosphoinositolglycan-peptide with insulin like activity HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-24 EP claimed
EP-0295092-B1 SKIN TREATMENT COMPOSITION UNILEVER PLC (GB) 1992-09-23 EP claimed
EP-0335554-B1 COSMETIC COMPOSITION UNILEVER PLC (GB) 1992-07-08 EP claimed
US-5080889-A Oil, oxidation resistance, stability KAO CORPORATION (JP) 1992-01-14 US claimed
EP-0391431-A1 Diacylglycerin and cosmetic composition KAO CORPORATION (JP) 1990-10-10 EP claimed
EP-0388778-A2 Preparation of dioxolane derivatives F. HOFFMANN-LA ROCHE AG (CH) 1990-09-26 EP claimed
WO-1990009981-A1 PREPARATION OF OPTICALLY ACTIVE GLYCEROL DERIVATIVES ISIS INNOVATION LIMITED (GB) 1990-09-07 WO claimed
EP-0319126-A2 Process for preparation of polyol fatty acid ester and glyceride mixture obtained Kao Corporation (JP) 1989-06-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002430-A1 METHOD FOR PRODUCING PROTEIN COMPOSITIONS CETP, IDE, LIPA FDPS 253/4885GGPS1 800/4885LMNA 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.